

An AACR Special Conference Aging and Cancer November 17-20, 2022 San Diego, CA



Current as of November 16, 2022

[R] – Remote Presentation Only

Poster Session A (To be presented on November 18 from 5:00-6:30 p.m. PT)

Aging in the Tumor Microenvironment

A002 Physical and Metabolic Aspects of Therapy Induced Senescence and Polyploidy in an Evolving Tumor Microenvironment. Michelle Dawson. Brown University, Providence, RI, United States.

A003 Integrating noise into a signal: Luminal epithelial cells integrate variable responses to aging into stereotypical changes that underly breast cancer susceptibility. Mark LaBarge. Beckman Research Institute at City of Hope, Duarte, CA, United States.

**A004** Identification and characterization of the cancer permissive environment in companion dogs. Jaime Modiano. University of Minnesota and Knine Biotechnology, Minneapolis, MN, United States.

A005 The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma. Manoela Tiago. Thomas Jefferson University, Philadelphia, PA, United States.

## **DNA Repair**

A006 LINC00261 acts as a surrogate biomarker for tumor DNA mutational burden and immunotherapeutic response in lung adenocarcinoma. Jonathan Castillo. Department of Translational Genomics, Department of Surgery (Thoracic Division), Norris Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

Effect of Racial Injustice and Stress on Cancer

A009 Association of Neighborhood Disadvantage with Biomarkers of Biological Aging and Chronic Stress among Breast Cancer Survivors. [R] Jie Shen. VCU, Richmond, VA, United States.

A010 Association of Allostatic Load and Overall Cancer Risk Among Women during the Menopausal Transition. [R] Jie Shen. VCU, Richmond, VA, United States.

**A011** Lifestyle behavior change interventions among adult rural cancer survivors: A systematic review. Samantha Werts. Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, United States.

### **Inflammation and Aging**

A012 Differences in attention, processing speed, and executive function in older breast cancer survivors compared to controls is partially explained by plasma IL-6: The Thinking and Living







with Cancer (TLC) Study. Judith Carroll. University of California, Los Angeles, Los Angeles, CA, United States.

**A013** Sex-dependent hematopoietic stem cell aging and leukemogenic potential. WenYong Chen. Beckman Research Institute, City of Hope, Duarte, CA, United States.

# A014 Cytokines surge in the blood years prior to a cancer diagnosis in elderly

individuals. Guangbo Chen. Institute for Immunology, Transplantation and Infection, Stanford University, Stanford, CA, United States.

A015 Age-associated molecular changes may predispose the ovary to malignant transformation leading to ovarian cancer (OVCA). Jessica Ramirez. Rush University, Chicago, IL, United States.

### Other

**A016** Aging-dependent emergent mechanical properties of single epithelial cells exploited for detection of breast cancer susceptibility. Stefan Hinz. City of Hope, North Hollywood, CA, United States.

A017 The geospatial analysis of the socioeconomic status and its impact on prostate cancer prevalence in Alabama. Manoj Mishra. Alabama State University, Montgomery, AL, United States.

**A018** Abiraterone vs Enzalutamide: Does age impact one treatment over another? Nikita Nikita. Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, PA, United States.

**A019** Cancer survivor-specific dietary patterns and risk of premature aging in adult survivors of childhood cancer: St. Jude lifetime (SJLIFE) cohort. Yikyung Park. Washington University School of Medicine, St. Louis, MO, United States.

A020 Thermostable Chitosan-L-Asparaginase conjugate from Aspergillus fumigatus is a novel structurally stable composite for abolishing acrylamide formation in French fried potatoes. Mohamed Soud. EFBL, Zagazig, AB, Egypt.

A021 Older adult-specific microbes correlate with treatment response and markers of T-cell senescence in NSCLC. Daniel Spakowicz. The Ohio State University, Columbus, OH, United States.

A022 Proteomic age acceleration associated with all-cause mortality in cancer survivors in the Atherosclerosis Risk in Communities (ARIC) Study. [R] Anna Prizment. University of Minnesota, Minneapolis, MN, United States.

**A023** Analysis of survival and prognostic factors for patients with non-small cell lung cancer and brain metastasis: 10-year experience in a single institution. Seung Ho Yang. St. Vincent's Hospital, The Catholic University of Korea, Suwon, Republic of Korea.







**A024** Enrollment of older adults in non-small cell lung cancer (NSCLC) clinical trials compared with population-based U.S. incidence. Felice Yang. Oncology Center of Excellence, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, MD, United States.

A025 Enrollment of older adults in small cell lung cancer (SCLC) clinical trials compared with population-based U.S. incidence estimates. Felice Yang. Oncology Center of Excellence, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, MD, United States.

#### Somatic Mutations and the Aging Process

A026 History of blood transfusion and the risk of developing hematologic cancers in the United States: A cross-sectional study using the NHANES database. [R] Amr Ebied. University of South Florida, Tampa, FL, United States.

A027 Clonal Hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: analysis of the PREMIS study. [R] Julieta Rodriguez. Gustave Roussy Cancer Campus, Paris, France.

**A028** Incidental detection of age-related somatic genomic alterations in blood samples from dogs with and without cancer. Dana Tsui. PetDx, La Jolla, CA, United States.

A029 Characterization of an aging Puerto Rican cohort with cancer: Analyzing sociodemographic factors and concomitant comorbidities. [R] Humberto Nieves-Jimenez. Universidad Central del Caribe School of Medicine, Bayamon, Puerto Rico.







Poster Session B (To be presented on November 19 from 4:00-6:30 p.m. PT)

Cancer, Aging, and Metabolism

**B001** Elevated All-cause and Cardiovascular Mortality in Cancer Survivors with Sarcopenia. Dejana Braithwaite. University of Florida Health Cancer Center, Gainesville, FL, United States.

**B003** Causal effect of type II diabetes on prostate cancer in the East Asian population: A twosample Mendelian randomization study. Zhongyi Guo. Cornell University, Ithaca, NY, United States.

**B004** Sugar Intake and Premature Aging in Adult of Childhood Cancer in the St. Jude Lifetime (SJLIFE) Cohort. Tuo Lan. Washington University School of Medicine, St. Louis, MO, United States.

**B005** Integrative analysis reveals the potential role and prognostic value of GOLM1 in hepatocellular carcinoma. Yan Lin. Guangxi Medical University Cancer Hospital, Nanning, China.

**B006** Does TFPI1 Drive Development of Multiple Drug Resistant Cancer and can the Anaphase Promoting Complex Prevent It?. Mathew Lubachowski. University of Saskatchewan, Saskatoon, SK, Canada.

**B008** Autoimmune Disease and the Risk of Anal Cancer in the U.S. Elderly Population. Minkyo Song. National Cancer Institute, Bethesda, MD, United States.

**B009** A liver-tropic BCL-xL PROTAC effectively clears senescent hepatocytes and prevents NASH-driven HCC in mice. Yang Yang. University of Florida, Gainesville, FL, United States.

**B010** Association between temporal muscle thickness and overall survival in non-small cell lung cancer patients with brain metastasis. Seung Ho Yang. Department of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea.

**B011 Prognosis-related molecular subtypes and immune features associated with hepatocellular carcinoma**. Jiazhou Ye. Guangxi Cancer Hospital and Guangxi Medical University Affiliated Cancer Hospital, Nanning, China.

**Epigenetics and Aging** 

**B012** Advanced epigenetic aging in non-AIDS-defining cancer patients living with HIV. Anna Coghill. Moffitt Cancer Center, Tampa, FL, United States.

**B013** Epigenetic clocks and breast cancer outcomes: A scoping review. [R] Jennifer Daw. University of Arizona, Tucson, AZ, United States.

**B015** Racial differences in epigenetic aging and its impact on expression of T-cell inhibitory receptors. Ping-Ching Hsu. University of Arkansas for Medical Sciences, Little Rock, AR, United States.

American Association for Cancer Research Special Conference: AGING AND CANCER | November 17-20, 2022 | Hilton San Diego Bayfront | San Diego, CA





**B016** Aberrant age-related methylation leads to tumor predisposition in colorectal organoids. Daniel Petkovich. Johns Hopkins University, Baltimore, MD, United States.

San Diego, CA

**B017** Epigenetic age in peripheral blood among children, adolescent, and adult survivors of childhood cancer. Noel-Marie Plonski. St. Jude Children's Hospital, Memphis, TN, United States.

An AACR Special Conference Aging and Cancer

November 17-20, 2022

**B018** Long-Term Epigenetic Aging in Older Breast Cancer Survivors and Non-Cancer Controls: Preliminary Findings from the Thinking and Living with Cancer (TLC) Study. Kelly Rentscher. Medical College of Wisconsin, Milwaukee, WI, United States.

**B019** Aging-induced reprogramming of the cell of origin defines lung cancer evolution. Xueqian Zhuang. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

#### Senescence and Aging

**B020** Pre-malignant plasma cells exhibit a senescence-like phenotype and accumulation of transposable elements. Gabriel Alvares Borges. Mayo Clinic, Rochester, MN, United States.

**B021** Breast cancer survivors and expression of p16INK4a, DNA damage, and the SASP prior to and following treatment. Judith Carroll. University of California Los Angeles, Los Angeles, CA, United States.

**B022** Targeting Senescence Cells in Cancer and Aging by Conditionally Active Biologic Therapeutics. Jian Chen. BioAtla, Inc., San Diego, CA, United States.

**B023** Enhanced survival and adherence of melphalan-induced senescent-like dormant multiple myeloma cells co-cultured with bone marrow stromal cells. Angelo Guilatco. Mayo Clinic, Rochester, MN, United States.

**B024** Increasing cellular longevity in budding yeast by activating the Anaphase Promoting Complex. Rachel Harris. University of Saskatchewan, Saskatoon, SK, Canada.

**B025 CD28-negative T cells from head and neck cancer patients are functionally frail but not senescent**. Nicole Schmitt. Emory University, Atlanta, GA, United States.

**B026** SIWA318H, a novel advanced glycation end product (AGE) specific antibody, targets cancer and senescent cells in the tumor microenvironment and exhibits potent antitumor activity in a humanized mouse model for pancreatic cancer. [R] Gabriela Rossi. SIWA Therapeutics, Chicago, IL, United States.